Kopran Reports Declining Profits and Rising Interest Expenses in March 2025 Results

Kopran, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results indicate a notable shift in the company's financial standing, as reflected in the adjustments to its evaluation.
The Profit Before Tax (PBT) for the quarter stands at Rs 10.45 crore, showing a significant decline compared to the previous year. Similarly, the Profit After Tax (PAT) for the latest six months is reported at Rs 20.08 crore, which also reflects a downward trend year on year. The company's net sales for the quarter reached Rs 172.36 crore, indicating a contraction compared to the same period last year.

Additionally, the interest expenses have risen to Rs 2.77 crore, marking the highest level in the last five quarters. This increase in interest costs suggests a rise in borrowings, which may impact the company's financial health moving forward. The operating profit to interest ratio has also reached its lowest point in recent quarters, indicating challenges in managing interest payments.

Overall, Kopran's recent financial results have led to a revision in its score, highlighting the underlying trends that may affect its future performance.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.